131 related articles for article (PubMed ID: 37767643)
21. Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy.
Chiuppesi F; Ortega-Francisco S; Gutierrez MA; Li J; Ly M; Faircloth K; Mack-Onyeike J; La Rosa C; Thomas S; Zhou Q; Drake J; Slape C; Fernando P; Rida W; Kaltcheva T; Grifoni A; Sette A; Patterson A; Dempsey S; Ball B; Ali H; Salhotra A; Stein A; Nathwani N; Rosenzweig M; Nikolaenko L; Al Malki MM; Dickter J; Nanayakkara DD; Puing A; Forman SJ; Taplitz RA; Zaia JA; Nakamura R; Wussow F; Diamond DJ; Dadwal SS
Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766168
[TBL] [Abstract][Full Text] [Related]
22. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
23. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S
J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053
[TBL] [Abstract][Full Text] [Related]
24. SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation.
Balashov D; Trakhtman P; Livshits A; Kovalenko I; Tereshenko G; Solopova G; Petraikina E; Maschan A; Novichkova G
Transfus Apher Sci; 2021 Feb; 60(1):102983. PubMed ID: 33153902
[TBL] [Abstract][Full Text] [Related]
25. SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity.
Steiner S; Schwarz T; Corman VM; Gebert L; Kleinschmidt MC; Wald A; Gläser S; Kruse JM; Zickler D; Peric A; Meisel C; Meyer T; Staudacher OL; Wittke K; Kedor C; Bauer S; Besher NA; Kalus U; Pruß A; Drosten C; Volk HD; Scheibenbogen C; Hanitsch LG
Front Immunol; 2022; 13():840126. PubMed ID: 35359967
[TBL] [Abstract][Full Text] [Related]
26. Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy.
Macková J; Hainz P; Kryštofová J; Roubalová K; Šťastná-Marková M; Vaníková Š; Musil J; Vydra J; Němečková Š
Leuk Res; 2023 Jul; 130():107314. PubMed ID: 37216792
[TBL] [Abstract][Full Text] [Related]
27. Treatment of immunocompromised COVID-19 patients with convalescent plasma.
Fung M; Nambiar A; Pandey S; Aldrich JM; Teraoka J; Freise C; Roberts J; Chandran S; Hays SR; Bainbridge E; DeVoe C; Roque Gardner A; Yokoe D; Henrich TJ; Babik JM; Chin-Hong P
Transpl Infect Dis; 2021 Apr; 23(2):e13477. PubMed ID: 32989856
[TBL] [Abstract][Full Text] [Related]
28. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.
Piñana JL; Martino R; Vazquez L; López-Corral L; Pérez A; Chorão P; Avendaño-Pita A; Pascual MJ; Sánchez-Salinas A; Sanz-Linares G; Olave MT; Arroyo I; Tormo M; Villalon L; Conesa-Garcia V; Gago B; Terol MJ; Villalba M; Garcia-Gutierrez V; Cabero A; Hernández-Rivas JÁ; Ferrer E; García-Cadenas I; Teruel A; Navarro D; Cedillo Á; Sureda A; Solano C;
Bone Marrow Transplant; 2023 May; 58(5):567-580. PubMed ID: 36854892
[TBL] [Abstract][Full Text] [Related]
30. Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.
Zimmerli A; Monti M; Fenwick C; Eckerle I; Beigelman-Aubry C; Pellaton C; Jaton K; Dumas D; Stamm GM; Infanti L; Andreu-Ullrich H; Germann D; Mean M; Vollenweider P; Stadelmann R; Prella M; Comte D; Guery B; Gachoud D; Rufer N
Front Immunol; 2021; 12():613502. PubMed ID: 33968017
[TBL] [Abstract][Full Text] [Related]
31. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.
Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI
Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987
[TBL] [Abstract][Full Text] [Related]
32. Favorable outcomes of COVID-19 in vaccinated hematopoietic stem cell transplant recipients: A single-center experience.
Tan JY; Wee LE; Tan YH; Conceicao EP; Lim FWI; Chen Y; Than H; Quek JKS; Nagarajan C; Goh YT; Hwang WYK; Phua GC; Chung SJ; Tan TT; Linn YC; Ho AYL; Tan BH
Transpl Infect Dis; 2023 Jun; 25(3):e14024. PubMed ID: 36715661
[TBL] [Abstract][Full Text] [Related]
33. Antiviral combination therapies for persistent COVID-19 in immunocompromised patients.
Focosi D; Maggi F; D'Abramo A; Nicastri E; Sullivan DJ
Int J Infect Dis; 2023 Dec; 137():55-59. PubMed ID: 37778409
[TBL] [Abstract][Full Text] [Related]
34. Prolonged SARS-CoV-2 Infection in a CAR T-Cell Therapy Recipient.
Abbasi J
JAMA; 2021 Mar; 325(10):924. PubMed ID: 33687450
[No Abstract] [Full Text] [Related]
35. COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
Rnjak D; Ravlić S; Šola AM; Halassy B; Šemnički J; Šuperba M; Hećimović A; Kurolt IC; Kurtović T; Mačak Šafranko Ž; Polančec D; Bendelja K; Mušlin T; Jukić I; Vuk T; Zenić L; Artuković M
Transfus Clin Biol; 2021 Aug; 28(3):264-270. PubMed ID: 33901641
[TBL] [Abstract][Full Text] [Related]
36. COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.
Hall VG; Teh BW
J Infect Dis; 2023 Aug; 228(Suppl 1):S55-S69. PubMed ID: 37539765
[TBL] [Abstract][Full Text] [Related]
37. Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019.
Bloch EM; Focosi D; Shoham S; Senefeld J; Tobian AAR; Baden LR; Tiberghien P; Sullivan DJ; Cohn C; Dioverti V; Henderson JP; So-Osman C; Juskewitch JE; Razonable RR; Franchini M; Goel R; Grossman BJ; Casadevall A; Joyner MJ; Avery RK; Pirofski LA; Gebo KA
Clin Infect Dis; 2023 Jun; 76(11):2018-2024. PubMed ID: 36740590
[TBL] [Abstract][Full Text] [Related]
38. Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation.
Huang A; Cicin-Sain C; Pasin C; Epp S; Audigé A; Müller NJ; Nilsson J; Bankova A; Wolfensberger N; Vilinovszki O; Nair G; Hockl P; Schanz U; Kouyos RD; Hasse B; Zinkernagel AS; Trkola A; Manz MG; Abela IA; Müller AMS
Transplant Cell Ther; 2022 Apr; 28(4):214.e1-214.e11. PubMed ID: 35092892
[TBL] [Abstract][Full Text] [Related]
39. Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19.
Haggenburg S; Hofsink Q; Lissenberg-Witte BI; Broers AEC; van Doesum JA; van Binnendijk RS; den Hartog G; Bhoekhan MS; Haverkate NJE; Burger JA; Bouhuijs JH; Smits GP; Wouters D; van Leeuwen EMM; Bontkes HJ; Kootstra NA; Zweegman S; Kater AP; Heemskerk MHM; Groen K; van Meerten T; Mutsaers PGNJ; Beaumont T; van Gils MJ; Goorhuis A; Rutten CE; Hazenberg MD; Nijhof IS;
JAMA Oncol; 2022 Oct; 8(10):1477-1483. PubMed ID: 35951338
[TBL] [Abstract][Full Text] [Related]
40. Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy.
Bošnjak B; Odak I; Ritter C; Stahl K; Graalmann T; Steinbrück L; Blasczyk R; Falk CS; Schulz TF; Wedemeyer HH; Cornberg M; Ganser A; Förster R; Koenecke C
Front Immunol; 2021; 12():721738. PubMed ID: 34456929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
